Floatz logo

Durvalumab

Radiation-Induced Pneumonitis

Roswell Park Cancer Institutemonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Radiation-Induced Pneumonitis cohort.

Asset / SponsorPhaseRating
Alpha Tocopherol
University Health Network, Toronto
Phase 2CCC
[68ga]cbp8
Massachusetts General Hospital
Phase 2CCC
Nintedanib
Roswell Park Cancer Institute
Phase 2CCC
Pentoxifylline
University Health Network, Toronto
Phase 2CCC

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →